Edesa Biotech (NASDAQ:EDSA) Shares Down 0.4% - Should You Sell?Market Beat·Jul 23 at 11:40 PMEDSA+1.90%STT-0.40%
Top Biotech Gainers: BOLD Begins Anew, MNPR NDA Filing On Track, GALT Soars On FDA Alignmentrttnews·Jun 23 at 10:15 PMGALT-2.59%EDSA+1.90%
Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors | EDSA Stock NewsStockTitan·Jun 11 at 12:15 AMEDSA+1.90%
Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury | EDSA Stock NewsStockTitan·Jun 5 at 12:20 AMEDSA+1.90%
MTVA Gains Weight, CODX Takes A Shot At Ebola, EDSA To Reveal New Data, BDTX On Watchrttnews·May 20 at 04:04 AMADIL+1.08%BDTX-1.70%
12 Health Care Stocks Moving In Tuesday's Intraday Sessionbenzinga_article·May 19 at 12:06 PMAMIX-4.45%WOK-6.86%
Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conference | EDSA Stock NewsStockTitan·May 19 at 12:15 AMEDSA+1.90%BIB+0.73%
